Nanoparticle-based drug delivery system for Oral Cancer: Mechanism, challenges, and therapeutic potential

Results in Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 102068 - 102068

Published: Jan. 1, 2025

Language: Английский

---

WBP5 Expression Influences Prognosis and Treatment Response in Head and Neck Squamous Cell Carcinoma

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 587 - 587

Published: Feb. 8, 2025

Head and neck squamous cell carcinoma (HNSCC) is characterized by complex genetic alterations. This study aimed to identify WBP5 as a promising therapeutic target evaluate the effect of expression on prognosis treatment response in HNSCC. Publicly available datasets were comprehensively analyzed investigate through comprehensive bioinformatics analysis functional validation. was particularly overexpressed HNSCC, Gene Expression Profiling Interactive Analysis version 2 (GEPIA2) database validated using multiple Omnibus (GEO) datasets. with UALCAN confirmed that significantly higher advanced cancer stages tumor grades than normal samples. A Kaplan-Meier demonstrated patients overexpressing had poor prognosis. Moreover, correlated overexpression epidermal growth factor receptor In vitro experiments revealed knockdown reduced FaDu proliferation viability. Furthermore, silencing enhanced cisplatin sensitivity, indicating its potential role chemoresistance. These results indicate could act prognostic marker viable Modulating may represent novel strategy enhance efficacy. Future studies should elucidate precise mechanisms action develop targeted therapies. integrated approach, combining publicly experimental validation provides strong evidence for clinical significance

Language: Английский

---

Real‐World Study of Later‐Line Anlotinib in R/M Head and Neck Squamous Cell Carcinoma

Oral Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

ABSTRACT Objectives The option is rare for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) failed to prior‐line immune checkpoint inhibitors (ICIs) cetuximab‐based treatment. efficacy of salvage therapy was unsatisfied. Materials Methods We collected the clinical data R/M HNSCC progressed from immunotherapy cetuximab therapy, retrospectively analyzed toxicity anlotinib‐based in these patients. Results In total, 24 eligible participants were accrued between October 2021 November 2024. Up cutoff time 1st, 2024, objective response rate 37.5%. Survival analysis revealed median progression‐free survival overall 4.27 months (95% CI, 1.53–7.01 months) 8.67 5.62–11.72 months), respectively. For safety, most common TRAEs any grades hypertension, hand–foot syndrome, gastrointestinal response, hemorrhage, hepatic dysfunction, fatigue. Grade 3 more observed (12.5%) patients, no 5 occurred. Conclusions Our observations indicated that had considerable well tolerance ICIs might be acted as a novel potentially effective later‐line treatment HNSCC.

Language: Английский

---

Identifying the Effects of Montelukast in Head and Neck Cancer Cells

Dicle Medical Journal / Dicle Tip Dergisi, Journal Year: 2025, Volume and Issue: 52(1), P. 87 - 94

Published: March 13, 2025

Objective: Head and neck squamous cell carcinoma (HNSCCs) are one of the most common cancer types worldwide. There different treatment approaches including drug repurposing against HNSCCs. In this study, we aim to evaluate montelukast effect on HNSCC lines by proliferative capacity, self-renewal potential, cycle dynamics. Methods: UM-SCC-47 HSC-3 were cultured treated with 10 uM montelukast. Control cells investigated colony formation assay, sphere assay. Stemness-related markers detected via qRT-PCR analysis was performed flow cytometry. Results: The assay demonstrated that group smaller organized compared control. NANOG SOX2 mRNA levels reduced whereas KLF4 OCT3/4 increased. Colony in group. Cell arrested S phase montelukast-treated groups. Conclusion: Montelukast at a concentration μM impacted several functional properties head cells, highlighting its potential effects context. Future studies should explore broader range concentrations better understand therapeutic dose-dependent effects.

Language: Английский

---

Smell and Taste Impairments in Head and Neck Cancer Patients—A Scoping Review

Nutrients, Journal Year: 2025, Volume and Issue: 17(6), P. 1087 - 1087

Published: March 20, 2025

Head and neck cancer affects millions worldwide. The risk factors are numerous, including smoking, alcohol consumption, human papillomavirus to name a few. While improved preventative, diagnostic, treatment methods have decreased mortality rates, the treatments (chemotherapy, radiotherapy, or surgery) often result in smell and/or taste impairments. These can impact quality of life during after treatment. A scoping review was performed understand current research future directions regarding impairments head patients. PRISMA guidelines were followed Rayyan.ai used search compile journal articles. Three databases, EBSCOhost, Google Scholar, PubMed, also searched. Search terms included smell, taste, dysgeusia, ageusia, hypogeusia, parosmia, anosmia, hyposmia, dysosmia, cancer. total 1580 articles found through 8022 three which manually screened. Articles assessing patients with different malignancy, benign tumors, pediatric populations, animal studies, abstracts, excluded. 47 using this strategy. Of those we identified, 37 discussed impairments, 12 3 for All concluded that there some alteration due their However, specific qualities (sweet, sour, salty, bitter) impaired, whether function returned baseline, led varied. For studies assessed results Some significant objective while others no impairment. Zinc sulfate not be an effective option impairments; however, liposomal spray showed potential. Future should aim types lead chemosensory alterations negatively patient’s nutritional status, preventative measures changes.

Language: Английский

---

Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: March 27, 2025

Head and neck cancer (HNC) critically affects patient survival quality of life, highlighting the need for optimized perioperative interventions. While conventional therapies face limitations in specificity toxicity, nanotechnology has emerged as a revolutionary approach. Preoperative application tumor-targeting nanoprobes enables molecular-level lesion identification via biomarker-specific conjugation spatially resolved fluorescence quantification. Intraoperatively, fluorescent nanomaterials enhance surgical precision through selective tumor accumulation, delineating malignant margins real time. Postoperatively, engineered nanocarriers improve therapeutic outcomes by delivering drugs with spatial control, minimizing off-target effects, enabling multimodal synergies. These nanotechnology-driven strategies collectively address critical challenges HNC management, including diagnostic sensitivity, intraoperative visualization, postoperative recurrence. Their inherent advantages—precision targeting, reduced systemic multifunctional integration—establish them cornerstone tools modern oncology. Future advancements nanomaterial design biocompatibility are poised to further refine efficacy, rates, patient-centered outcomes.

Language: Английский

---

ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is associated with immune infiltration

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 12, 2025

Adenosine A2B receptor (ADORA2B), a G protein-coupled receptor, is implicated in tumor progression and immune regulation various cancers. However, its specific role head neck squamous cell carcinoma (HNSC) remains largely unexplored. This study aims to elucidate the expression profile, prognostic value, modulatory role, therapeutic potential of ADORA2B HNSC. Comprehensive bioinformatics analyses were performed using TCGA GEO datasets evaluate expression, clinical correlations, significance Weighted gene co-expression network analysis (WGCNA) functional enrichment conducted explore ADORA2B-associated pathways. Immune infiltration was assessed via ESTIMATE single-sample set (ssGSEA). checkpoint blockade (ICB) therapy sensitivity drug analyzed IMvigor210 NCI-60 databases, respectively. In vitro experiments, including siRNA-mediated knockdown, CCK-8 assays, colony formation, wound healing validate oncogenic ADORA2B. significantly overexpressed HNSC tissues compared adjacent normal tissues, correlated with advanced stage as well poor overall survival (OS) progression-free (PFS). Functional revealed significant downregulation immune-related pathways high groups. High associated more immunosuppressive microenvironment (TME), characterized by lower stromal scores reduced infiltration. Immunotherapy response demonstrated that patients exhibited poorer outcomes following ICB therapy. Drug identified several agents, Ixazomib citrate, Masitinib, others, candidates for patients. experiments confirmed knockdown inhibited proliferation, migration, underscoring critical progression. key driver HNSC, contributing an TME. Its prognosis immunotherapy efficacy. Targeting may enhance overcome treatment resistance, highlighting diagnostic, prognostic, biomarker.

Language: Английский

---

C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0322701 - e0322701

Published: May 7, 2025

Head and neck squamous cell carcinoma (HNSC) is a prevalent aggressive malignancy with poor prognosis, underscoring the need for novel biomarkers therapeutic strategies. This study investigates role of C16orf74 as potential diagnostic prognostic biomarker in HNSC. Bioinformatics analyses revealed that significantly overexpressed HNSC associated advanced disease stages, therapy resistance, shorter overall progression-free survival. A nomogram integrating expression clinicopathological features demonstrated robust predictive performance. Functional enrichment immune infiltration suggest high might contribute to an immunosuppressive tumor microenvironment by reducing key populations, such B cells, T natural killer which are critical anti-tumor immunity. Moreover, was inversely checkpoint immunotherapy response, highlighting its blockade (ICB) efficacy. Drug sensitivity identified agents, including arsenic trioxide, carmustine, vincristine, quercetin, carboplatin patients expression. These findings highlight target improve management.

Language: Английский

---

Preclinical Therapeutic Efficacy of External Beam Radiotherapy with Anti-Pd-L1 Inhibition in a Syngeneic Head and Neck Cancer Model

Published: Jan. 1, 2025

Language: Английский

---